QuantumScape Corporation (QS) Presents at Morgan Stanley's 14th Annual Laguna Conference Transcript

QuantumScape highlighted progress toward commercialization of its solid-state lithium-metal batteries, including the launch of its highly automated Eagle pilot line in San Jose. The company expanded beyond its core automotive focus into data centers and Advanced Solutions, spanning aerospace, defense, robotics, consumer electronics and medical devices. It also cited a multiyear research agreement with Honda announced in June, supporting its automotive development pipeline.

Analysis

QS is transitioning from a single end-market technology option into a broader qualification story, but this does not automatically improve near-term economics. Automotive customers optimize for validated cycle life, yield, pack-level cost and warranty liability; data-center and defense customers can tolerate higher cell cost, yet require equally rigorous reliability, supply assurance and certification. The diversification narrative can support the multiple over 1-3 months, but only independently disclosed performance, customer-funded development milestones, or binding capacity commitments can alter the cash-burn valuation debate.

The key second-order issue is manufacturing transferability. If the separator/process platform can be deployed across small-format, premium applications before automotive scale, QS may establish a real learning curve and non-dilutive customer funding; if each vertical requires materially different cell architecture or qualification work, management breadth becomes a cost center rather than optionality. HMC's strategic value is therefore less about near-term unit revenue than whether it validates a path from laboratory specifications to automotive-grade manufacturing yield, a hurdle that has historically separated battery claims from investable cell businesses.

Consensus may overreact positively to adjacent-market optionality because these markets are smaller and procurement cycles can be slow. Conversely, QS remains unusually convex if it reports repeatable pilot-line yield, throughput and externally verified cell performance: evidence that reduces the probability of future equity raises would drive a larger rerating than another partnership announcement. Over 6-18 months, the relevant competitive comparison is not legacy lithium-ion suppliers but other solid-state aspirants such as SLDP and Toyota's battery program; the winner will be the first to demonstrate manufacturability at cost, not the best single-cell specification.

Key Decisions for Investors

• Maintain QS as a watch-list long rather than add on conference-driven strength; initiate only after disclosure of repeatable pilot-line throughput/yield and a funded customer qualification milestone. Target a 6-12 month 2:1 upside/downside profile, with thesis invalidated by increased cash-burn guidance, a dilutive financing, or delayed customer sampling.
• For investors seeking exposure now, use a defined-risk structure: buy QS 9-12 month call spreads financed only with a modest premium budget, rather than common equity. The catalyst window is the next two earnings reports and any externally verifiable manufacturing data; total premium loss is the appropriate risk limit if commercialization timing slips.
• Avoid treating HMC as a meaningful earnings lever in the next 12 months. Monitor for a binding licensing, joint-development funding, or capacity agreement; absent those terms, the relationship is strategic validation rather than a basis for changing HMC estimates.
• Set an alert for any disclosure separating prototype performance from production yield, scrap and unit-cost metrics. A favorable cell-performance update without those manufacturing metrics should be sold into, while quantified yield improvement would justify revisiting a QS long.